Xamoterol (Corwin - ICI) is a selective β1, adrenoceptor partial agonist which was at first promoted for the treatment of chronic heart failure, except in severe cases. In May the Committee on Safety of Medicines (CSM) and the manufacturer recommended much more restricted use1 and as we went to press it was being suggested in the media that the drug should be withdrawn. We here discuss whether it should be used or not.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.